Karyopharm Phase 3 SENTRY myelofibrosis trial results set for ASCO late-breaking oral presentation

Karyopharm Therapeutics, Inc.

Karyopharm Therapeutics, Inc.

KPTI

0.00
  • Karyopharm flagged Phase 3 SENTRY trial results for a late-breaking oral presentation at ASCO 2026.
  • Data have not yet been presented; ASCO scheduled abstract release for June 2, 2026, ahead of presentation later that morning.
  • SENTRY tested once-weekly selinexor with ruxolitinib versus placebo with ruxolitinib in JAK inhibitor-naïve myelofibrosis.
  • Study focused on reducing spleen enlargement, easing symptom burden.
  • ASCO slot positions selinexor-ruxolitinib combination as a potential differentiated first-line option in myelofibrosis, a market currently dominated by JAK inhibitors.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Karyopharm Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202604211032PR_NEWS_USPR_____NE39350) on April 21, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.